Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2026-01-01 @ 6:42 PM
Study NCT ID:
NCT04949256
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-15
First Post:
2021-06-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000077277', 'term': 'Esophageal Squamous Cell Carcinoma'}, {'id': 'C565324', 'term': 'Parkinson Disease 4, Autosomal Dominant Lewy Body'}], 'ancestors': [{'id': 'D002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D018307', 'term': 'Neoplasms, Squamous Cell'}, {'id': 'D004938', 'term': 'Esophageal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582435', 'term': 'pembrolizumab'}, {'id': 'C531958', 'term': 'lenvatinib'}, {'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D000077150', 'term': 'Oxaliplatin'}, {'id': 'D002955', 'term': 'Leucovorin'}, {'id': 'D058766', 'term': 'Levoleucovorin'}, {'id': 'D017239', 'term': 'Paclitaxel'}], 'ancestors': [{'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D005575', 'term': 'Formyltetrahydrofolates'}, {'id': 'D013763', 'term': 'Tetrahydrofolates'}, {'id': 'D005492', 'term': 'Folic Acid'}, {'id': 'D011622', 'term': 'Pterins'}, {'id': 'D011621', 'term': 'Pteridines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D003067', 'term': 'Coenzymes'}, {'id': 'D045762', 'term': 'Enzymes and Coenzymes'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 864}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2021-07-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-06-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-08', 'studyFirstSubmitDate': '2021-06-29', 'studyFirstSubmitQcDate': '2021-06-29', 'lastUpdatePostDateStruct': {'date': '2025-12-15', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2021-07-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-05-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1 (FP and TP Safety Run-in): Number of Participants With Dose Limiting Toxicities (DLTs)', 'timeFrame': 'Up to ~21 days', 'description': 'Hematologic DLTs are defined as Grade 4 neutropenia lasting for ≥7 days, Grade 3 or Grade 4 febrile neutropenia, Grade 3 thrombocytopenia with bleeding, Grade 4 thrombocytopenia, or Grade 4 anemia. Other nonhematologic toxicities considered a DLT include any other Grade 4 or Grade 5 toxicity, Grade 3 toxicities lasting \\>3 days (excluding nausea, vomiting, and diarrhea controlled by medical intervention within 72 hours, and Grade 3 rash in the absence of desquamation with no mucosal involvement), Grade 3 hypertension not able to be controlled by medication, ≥Grade 3 gastrointestinal perforation, ≥Grade 3 wound dehiscence requiring medical or surgical intervention, any grade thromboembolic event or any Grade 3 nonhematologic laboratory value requiring medical intervention or hospitalization. The number of participants in Part 1 with DLTs will be presented.'}, {'measure': 'Part 1 (FP and TP Safety Run-in): Number of Participants With Adverse Events (AEs)', 'timeFrame': 'Up to ~53 months', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 1 with AEs will be presented.'}, {'measure': 'Part 1 (FP and TP Safety Run-in): Number of Participants who Discontinued Study Treatment Due to an AE', 'timeFrame': 'Up to ~53 months', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 1 who discontinue study treatment due to an AE will be presented.'}, {'measure': 'Part 2 (Main Study): Overall Survival (OS) in all Participants', 'timeFrame': 'Up to ~48 months', 'description': 'OS is defined as the time from randomization to death due to any cause. OS in Part 2 for all randomized participants will be presented.'}], 'secondaryOutcomes': [{'measure': 'Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants', 'timeFrame': 'Up to ~42 months', 'description': 'PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS in Part 2 for all randomized participants will be presented.'}, {'measure': 'Part 2 (Main Study): Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR in all Participants', 'timeFrame': 'Up to ~42 months', 'description': 'ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 adjusted to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by BICR. ORR in Part 2 for all randomized participants will be presented.'}, {'measure': 'Part 2 (Main Study): Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR in all Participants', 'timeFrame': 'Up to ~42 months', 'description': 'For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 by BICR, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. DOR in Part 2 for all randomized participants will be presented.'}, {'measure': 'Part 2 (Main Study): OS in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10', 'timeFrame': 'Up to ~48 months', 'description': 'OS is defined as the time from randomization to death due to any cause. OS in Part 2 for randomized participants with PD-L1 CPS ≥10 will be presented.'}, {'measure': 'Part 2 (Main Study): PFS per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥10', 'timeFrame': 'Up to ~42 months', 'description': 'PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS in Part 2 for randomized participants with PD-L1 CPS ≥10 will be presented.'}, {'measure': 'Part 2 (Main Study): ORR per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥10', 'timeFrame': 'Up to ~42 months', 'description': 'ORR is defined as the percentage of participants with CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 adjusted to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by BICR. ORR in Part 2 for randomized participants with PD-L1 CPS ≥10 will be presented.'}, {'measure': 'Part 2 (Main Study): DOR per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥10', 'timeFrame': 'Up to ~42 months', 'description': 'For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 by BICR, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. DOR in Part 2 for randomized participants with PD-L1 CPS ≥10 will be presented.'}, {'measure': 'Part 2 (Main Study): Number of Participants With AEs', 'timeFrame': 'Up to ~53 months', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 2 with AEs will be presented.'}, {'measure': 'Part 2 (Main Study): Number of Participants who Discontinued Study Treatment Due to an AE', 'timeFrame': 'Up to ~53 months', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 2 who discontinue study treatment due to an AE will be presented.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['programmed cell death 1 (PD-1, PD1)', 'programmed cell death ligand 1 (PD-L1, PDL1)'], 'conditions': ['Metastatic Esophageal Squamous Cell Carcinoma']}, 'referencesModule': {'references': [{'pmid': '38695479', 'type': 'DERIVED', 'citation': 'Sun JM, Adenis A, C Enzinger P, Shah MA, Kato K, Bennouna J, Doi T, Hawk NN, Yu L, Shah S, Bhagia P, Shen L. LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncol. 2024;20(35):2709-2721. doi: 10.2217/fon-2022-1148. Epub 2024 May 2.'}], 'seeAlsoLinks': [{'url': 'https://www.merckclinicaltrials.com/', 'label': 'Merck Clinical Trials Information'}, {'url': 'https://msd.trialsummaries.com/Study/StudyDetails?id=26316&tenant=MT_MSD_9011', 'label': 'Plain Language Summary'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma.\n\nThe primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).\n\nAs of Amendment 09, Study MK-7902-014 will begin close out activities. Any participant who discontinues study intervention for any reason will be discontinued from the study without further follow-up. Second Course and treatment beyond disease progression will no longer be offered. No safety concerns contributed to the termination of this study.', 'detailedDescription': 'There will be 2 parts to the study: the cisplatin and 5-fluorouracil (5-FU) (FP) and paclitaxel and cisplatin (TP) Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (FP and TP Safety Run-in), participants will be treated with pembrolizumab plus lenvatinib plus FP or TP. Dose-limiting toxicities, safety, and tolerability will be assessed.\n\nIn Part 2 (Main Study), participants (not including those participating in Part 1) will be treated with pembrolizumab plus lenvatinib plus chemotherapy or pembrolizumab plus chemotherapy. Efficacy, safety, and tolerability will be assessed.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus\n* Male participants are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or 90 days after the last dose of chemotherapy, whichever comes last; 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only and is greater than 90 days post chemotherapy, no male contraception is needed\n* Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP using a contraceptive method that is highly effective or is abstinent from heterosexual intercourse as their preferred and usual lifestyle during the intervention period and for at least 120 days after the last dose of pembrolizumab, 30 days after the last dose of lenvatinib, or 180 days after the last dose of chemotherapy, whichever occurs last, and agrees not to donate eggs during this period\n* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP≤150/90 millimeters of mercury (mm Hg) with no change in antihypertensive medications within 1 week prior to randomization\n* Has adequate organ function\n\nExclusion Criteria:\n\n* Has had previous therapy for locally advanced unresectable or metastatic esophageal cancer\n* Has locally advanced esophageal carcinoma\n* Has metastatic adenocarcinoma of the esophagus\n* Has direct invasion into adjacent organs such as the aorta or trachea\n* Has radiographic evidence of encasement of a major blood vessel, or of intratumoral cavitation\n* Has perforation risks or significant gastrointestinal (GI) bleeding\n* Has had clinically significant hemoptysis within 3 weeks prior to the first dose of study drug or tumor bleeding within 2 weeks prior to the first dose of study intervention\n* Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention\n* Has GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent\n* Has had major surgery, open biopsy, or significant traumatic injury within 3 weeks prior to first dose of study interventions\n* Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis\n* Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, or has a history of organ transplant, including allogeneic stem cell transplant\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has an active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed\n* Has a history of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease\n* Has poorly controlled diarrhea\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention\n* Has peripheral neuropathy ≥Grade 2\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has a known history of Hepatitis B or know active Hepatitis C virus infection\n* Has a weight loss of \\>20% within the last 3 months'}, 'identificationModule': {'nctId': 'NCT04949256', 'briefTitle': 'Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Sharp & Dohme LLC'}, 'officialTitle': 'A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma', 'orgStudyIdInfo': {'id': '7902-014'}, 'secondaryIdInfos': [{'id': 'MK-7902-014', 'type': 'OTHER', 'domain': 'MSD'}, {'id': 'LEAP-014', 'type': 'OTHER', 'domain': 'MSD'}, {'id': 'E7080-G000-320', 'type': 'OTHER', 'domain': 'Eisai'}, {'id': 'U1111-1280-1020', 'type': 'REGISTRY', 'domain': 'UTN'}, {'id': '2022-501342-29-00', 'type': 'REGISTRY', 'domain': 'EU CT'}, {'id': '2020-001911-26', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1: Pembrolizumab + Lenvatinib + Chemotherapy', 'description': "In the Induction phase, participants receive pembrolizumab 400mg intravenously (IV) every 6 weeks (Q6W) for 2 cycles (each cycle length = 6 weeks) plus Lenvatinib 8 mg orally (PO) once daily (QD) plus chemotherapy with FP (cisplatin 80 mg/m\\^2 and 5-FU 400 mg/m\\^2 followed by 2400 mg/m\\^2) or TP (paclitaxel 175 mg/m\\^2 and cisplatin 75 mg/m\\^2) IV every 3 weeks for 4 administrations at the investigator's discretion (approximately 12 weeks). In the Consolidation phase, participants receive pembrolizumab 400 mg IV Q6W for 16 cycles (each cycle length = 6 weeks) and Lenvatinib 20 mg PO until progressive disease or discontinuation (approximately 96 weeks).", 'interventionNames': ['Biological: Pembrolizumab', 'Drug: Lenvatinib', 'Drug: Cisplatin', 'Drug: 5-FU', 'Drug: Paclitaxel']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy', 'description': "In the Induction phase, participants receive pembrolizumab 400mg intravenously (IV) every 6 weeks (Q6W) for 2 cycles (each cycle length = 6 weeks) plus Lenvatinib 8 mg orally (PO) once daily (QD) plus chemotherapy with FP (cisplatin 80 mg/m\\^2 and 5-FU 4000 mg/m\\^2) or TP (paclitaxel 175 mg/m\\^2 and cisplatin 75 mg/m\\^2) IV every 3 weeks for 4 administrations or mFOLFOX6 (oxaliplatin 85 mg/m\\^2, 5-FU 400 mg/m\\^2 followed by 2400 mg/m\\^2, and leucovorin 400 mg/m\\^2 \\[or levoleucovorin 200 mg/m\\^2\\] once every 2 weeks \\[Q2W\\] for 6 administrations at the investigator's discretion (approximately 12 weeks). In the Consolidation phase, participants receive pembrolizumab 400 mg IV Q6W for 16 cycles (each cycle length = 6 weeks) and Lenvatinib 20 mg PO until progressive disease or discontinuation (approximately 96 weeks).", 'interventionNames': ['Biological: Pembrolizumab', 'Drug: Lenvatinib', 'Drug: Cisplatin', 'Drug: 5-FU', 'Drug: Oxaliplatin', 'Drug: Leucovorin', 'Drug: Levoleucovorin', 'Drug: Paclitaxel']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Part 2: Pembrolizumab + Chemotherapy', 'description': 'Participants receive pembrolizumab 400 mg IV every 6 weeks for 18 cycles (each cycle length = 6 weeks, approximately 2 years) plus chemotherapy with FP (cisplatin 80 mg/m\\^2 IV Q3W for up to 6 administrations \\[up to \\~18 weeks\\] and 5-FU 4000 mg/m\\^2 IV Q3W for up to 35 administrations \\[up to \\~2 years\\]) or TP (paclitaxel 175 mg/m\\^2 and cisplatin 75 mg/m\\^2 Q3W for up 6 administrations \\[up to \\~18 weeks\\]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m\\^2, 5-FU 400 mg/m\\^2 followed by 2400 mg/m\\^2 and leucovorin 400 mg/m\\^2 \\[or levoleucovorin 200 mg/m\\^2\\] IV Q2W for up to 52 administrations \\[approximately 2 years\\]).', 'interventionNames': ['Biological: Pembrolizumab', 'Drug: 5-FU', 'Drug: Oxaliplatin', 'Drug: Leucovorin', 'Drug: Levoleucovorin', 'Drug: Paclitaxel']}], 'interventions': [{'name': 'Pembrolizumab', 'type': 'BIOLOGICAL', 'otherNames': ['MK-3475', 'KEYTRUDA®'], 'description': '400 mg once every 6-week-cycle, via IV infusion.', 'armGroupLabels': ['Part 1: Pembrolizumab + Lenvatinib + Chemotherapy', 'Part 2: Pembrolizumab + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': 'Lenvatinib', 'type': 'DRUG', 'otherNames': ['MK-7902', 'E7080', 'LENVIMA®'], 'description': '8 mg QD (Induction) or 20 mg QD (Consolidation) via oral capsule.', 'armGroupLabels': ['Part 1: Pembrolizumab + Lenvatinib + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': 'Cisplatin', 'type': 'DRUG', 'otherNames': ['PLATINOL®'], 'description': "80 mg/m\\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.", 'armGroupLabels': ['Part 1: Pembrolizumab + Lenvatinib + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': '5-FU', 'type': 'DRUG', 'otherNames': ['ADRUCIL®'], 'description': "4000 mg/m\\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\\^2 Q2W via bolus IV infusion followed by 2400 mg/m\\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.", 'armGroupLabels': ['Part 1: Pembrolizumab + Lenvatinib + Chemotherapy', 'Part 2: Pembrolizumab + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': 'Oxaliplatin', 'type': 'DRUG', 'otherNames': ['ELOXATIN®'], 'description': "85 mg/m\\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.", 'armGroupLabels': ['Part 2: Pembrolizumab + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': 'Leucovorin', 'type': 'DRUG', 'otherNames': ['calcium folinate', 'folinic acid', 'WELLCOVORIN®'], 'description': "400 mg/m\\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.", 'armGroupLabels': ['Part 2: Pembrolizumab + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': 'Levoleucovorin', 'type': 'DRUG', 'otherNames': ['calcium levofolinate', 'levofolinic acid', 'FUSILEV®'], 'description': "200 mg/m\\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.", 'armGroupLabels': ['Part 2: Pembrolizumab + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}, {'name': 'Paclitaxel', 'type': 'DRUG', 'otherNames': ['TAXOL®', 'ONXAL®'], 'description': "175 mg/m\\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.", 'armGroupLabels': ['Part 1: Pembrolizumab + Lenvatinib + Chemotherapy', 'Part 2: Pembrolizumab + Chemotherapy', 'Part 2: Pembrolizumab + Lenvatinib + Chemotherapy']}]}, 'contactsLocationsModule': {'locations': [{'zip': '91010', 'city': 'Duarte', 'state': 'California', 'country': 'United States', 'facility': 'City of Hope ( Site 0102)', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'zip': '20010', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'MedStar Washington Hospital Center ( Site 0186)', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'James Graham Brown Cancer Center ( Site 0117)', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '40217', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Norton Cancer Institute ( Site 0116)', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '21224', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Johns Hopkins Bayview Medical Center ( Site 0152)', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '01655', 'city': 'Worcester', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'UMASS Memorial Medical Center ( Site 0120)', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}, {'zip': '08534', 'city': 'Pennington', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Capital Health Medical Center - Hopewell ( Site 0189)', 'geoPoint': {'lat': 40.32844, 'lon': -74.79072}}, {'zip': '13057', 'city': 'East Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'Hematology-Oncology Associates of CNY ( Site 0173)', 'geoPoint': {'lat': 43.06534, 'lon': -76.07853}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center ( Site 0132)', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Weill Cornell Medical College ( Site 0133)', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '18015', 'city': 'Bethlehem', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "St. Luke's University Health Network ( Site 0185)", 'geoPoint': {'lat': 40.62593, 'lon': -75.37046}}, {'zip': '15212', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'AHN Allegheny General Hospital ( Site 0164)', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Medical University of South Carolina-Hollings Cancer Center ( Site 0177)', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '23219', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'VCU Health Adult Outpatient Pavillion ( Site 0160)', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Seattle Cancer Care Alliance ( Site 0145)', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': 'B1884BBF', 'city': 'Berazategui', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0203)', 'geoPoint': {'lat': -34.76531, 'lon': -58.21278}}, {'zip': 'C1012AAR', 'city': 'CABA', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202)'}, {'zip': 'B7600FZO', 'city': 'Mar del Plata', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Instituto de Investigaciones Clinicas Mar del Plata ( Site 0205)', 'geoPoint': {'lat': -38.00042, 'lon': -57.5562}}, {'zip': 'S2000DEJ', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Fundacion Estudios Clinicos-Oncology ( Site 0215)', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': 'S2000DSV', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Sanatorio Parque ( Site 0206)', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': 'S2002KDS', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Hospital Provincial del Centenario ( Site 0217)', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': 'C1093AAS', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Fundacion Favaloro ( Site 0201)', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1426ABP', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Fundación Respirar ( Site 0216)', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'X5004BAL', 'city': 'Córdoba', 'country': 'Argentina', 'facility': 'Hospital Italiano de Córdoba ( Site 0218)', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': 'F5300COE', 'city': 'La Rioja', 'country': 'Argentina', 'facility': 'Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0221)', 'geoPoint': {'lat': -29.41328, 'lon': -66.85637}}, {'zip': 'J5400EBB', 'city': 'San Juan', 'country': 'Argentina', 'facility': 'Instituto San Marcos ( Site 0213)', 'geoPoint': {'lat': -31.53726, 'lon': -68.52568}}, {'zip': 'R3E 0V9', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'CancerCare Manitoba ( Site 0001)', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'M5G 2M9', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Princess Margaret Cancer Centre ( Site 0004)', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'G6V 3Z1', 'city': 'Lévis', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Hotel-Dieu de Levis ( Site 0013)', 'geoPoint': {'lat': 46.80326, 'lon': -71.17793}}, {'zip': '7500836', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'Fundacion Arturo Lopez Perez FALP ( Site 0403)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7510032', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'Oncovida ( Site 0413)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7550000', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8420383', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'country': 'Chile', 'facility': 'Bradford Hill Centro de Investigaciones Clinicas ( Site 0404)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '4800827', 'city': 'Temuco', 'state': 'Región de la Araucanía', 'country': 'Chile', 'facility': 'James Lind Centro de Investigacion del Cancer ( Site 0412)', 'geoPoint': {'lat': -38.73628, 'lon': -72.59738}}, {'zip': '4810218', 'city': 'Temuco', 'state': 'Región de la Araucanía', 'country': 'Chile', 'facility': 'Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0401)', 'geoPoint': {'lat': -38.73628, 'lon': -72.59738}}, {'zip': '230031', 'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'facility': 'Anhui Provincial Cancer Hospital ( Site 8058)', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '230031', 'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'facility': 'The Second Affiliated Hospital of Anhui Medical University ( Site 8026)', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '100142', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Beijing Cancer Hospital ( Site 8001)', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '350014', 'city': 'Fuzhou', 'state': 'Fujian', 'country': 'China', 'facility': 'Fujian Provincial Cancer Hospital ( Site 8029)', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'zip': '361004', 'city': 'Xiamen', 'state': 'Fujian', 'country': 'China', 'facility': 'Zhongshan Hospital Affiliated to Xiamen University ( Site 8055)', 'geoPoint': {'lat': 24.47979, 'lon': 118.08187}}, {'zip': '361003', 'city': 'Xiamen City, Fujian Province', 'state': 'Fujian', 'country': 'China', 'facility': 'The First Affiliated Hospital of Xiamen University ( Site 8003)', 'geoPoint': {'lat': 24.47979, 'lon': 118.08187}}, {'zip': '510080', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'The First Affiliated Hospital.Sun Yat-sen University ( Site 8047)', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510515', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Southern Medical University Nanfang Hospital ( Site 8031)', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '410013', 'city': 'Changsha', 'state': 'Hainan', 'country': 'China', 'facility': 'The Third Xiangya Hospital of Central South University ( Site 8046)', 'geoPoint': {'lat': 18.8093, 'lon': 110.017}}, {'zip': '570102', 'city': 'Haikou', 'state': 'Hainan', 'country': 'China', 'facility': 'The First Affiliated Hospital of Hainan Medical University ( Site 8042)', 'geoPoint': {'lat': 20.03421, 'lon': 110.34651}}, {'zip': '067055', 'city': 'Chengde', 'state': 'Hebei', 'country': 'China', 'facility': 'Affiliated Hospital of Chengde Medical Univeristy ( Site 8053)', 'geoPoint': {'lat': 40.9519, 'lon': 117.95883}}, {'city': 'Harbin', 'state': 'Heilongjiang', 'country': 'China', 'facility': 'Harbin Medical University Cancer Hospital ( Site 8009)', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'zip': '455000', 'city': 'Anyang', 'state': 'Henan', 'country': 'China', 'facility': 'Anyang Cancer Hospital ( Site 8006)', 'geoPoint': {'lat': 36.096, 'lon': 114.38278}}, {'zip': '471003', 'city': 'Luoyang', 'state': 'Henan', 'country': 'China', 'facility': 'The First Affiliated Hospital of Henan University of Science &Technology-Tumor ( Site 8036)', 'geoPoint': {'lat': 34.67345, 'lon': 112.43684}}, {'zip': '453100', 'city': 'Xinxiang', 'state': 'Henan', 'country': 'China', 'facility': 'The First Affiliated Hospital of Xinxiang Medical University ( Site 8018)', 'geoPoint': {'lat': 35.19033, 'lon': 113.80151}}, {'zip': '430030', 'city': 'Wuhan', 'state': 'Hubei', 'country': 'China', 'facility': 'Tongji Medical College Huazhong Uinversity Of Science and Technology ( Site 8025)', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '430079', 'city': 'Wuhan', 'state': 'Hubei', 'country': 'China', 'facility': 'Hubei Cancer Hospital ( Site 8014)', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '214122', 'city': 'Wuxi', 'state': 'Jiangsu', 'country': 'China', 'facility': 'Affiliated hospital of Jiangnan university ( Site 8049)', 'geoPoint': {'lat': 31.56887, 'lon': 120.28857}}, {'zip': '221000', 'city': 'Xuzhou', 'state': 'Jiangsu', 'country': 'China', 'facility': 'The Affiliated Hospital of Xuzhou Medical University ( Site 8015)', 'geoPoint': {'lat': 34.20442, 'lon': 117.28386}}, {'zip': '130012', 'city': 'Changchun', 'state': 'Jilin', 'country': 'China', 'facility': 'Jilin Cancer Hospital ( Site 8016)', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '250013', 'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'facility': 'Jinan Central Hospital ( Site 8052)', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '250117', 'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'facility': 'Shandong Cancer Hospital ( Site 8060)', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '272000', 'city': 'Jining', 'state': 'Shandong', 'country': 'China', 'facility': 'Affiliated Hospital of Jining Medical University ( Site 8017)', 'geoPoint': {'lat': 35.405, 'lon': 116.58139}}, {'zip': '276000', 'city': 'Linyi', 'state': 'Shandong', 'country': 'China', 'facility': 'Linyi Cancer Hospital- Medical Oncology Department ( Site 8051)', 'geoPoint': {'lat': 35.06306, 'lon': 118.34278}}, {'zip': '030000', 'city': 'Taiyuan', 'state': 'Shanxi', 'country': 'China', 'facility': 'Shanxi Provincial Cancer Hospital ( Site 8019)', 'geoPoint': {'lat': 37.86944, 'lon': 112.56028}}, {'zip': '610041', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'facility': 'West China Hospital of Sichuan University ( Site 8048)', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '300060', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'country': 'China', 'facility': 'Tianjin Medical University Cancer Institute & Hospital ( Site 8035)', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '830000', 'city': 'Ürümqi', 'state': 'Xinjiang', 'country': 'China', 'facility': 'The Affiliated Cancer Hospital of Xinjiang Medical University. ( Site 8041)', 'geoPoint': {'lat': 43.80096, 'lon': 87.60046}}, {'zip': '310016', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'facility': 'Sir Run Run Shaw Hospital ( Site 8021)', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '10108', 'city': 'San José', 'state': 'Provincia de San José', 'country': 'Costa Rica', 'facility': 'ICIMED-Oncology Research Unit ( Site 0903)', 'geoPoint': {'lat': 9.93388, 'lon': -84.08489}}, {'zip': '11303', 'city': 'San José', 'state': 'Provincia de San José', 'country': 'Costa Rica', 'facility': 'PROCLINICAL Pharma ( Site 0904)', 'geoPoint': {'lat': 9.93388, 'lon': -84.08489}}, {'zip': '10103', 'city': 'San José', 'country': 'Costa Rica', 'facility': 'CIMCA Centro de Investigacion y Manejo del Cancer ( Site 0902)', 'geoPoint': {'lat': 9.93388, 'lon': -84.08489}}, {'zip': '10103', 'city': 'San José', 'country': 'Costa Rica', 'facility': 'Onco Tech S A ( Site 0901)', 'geoPoint': {'lat': 9.93388, 'lon': -84.08489}}, {'zip': '2100', 'city': 'Copenhagen', 'state': 'Capital Region', 'country': 'Denmark', 'facility': 'Rigshospitalet ( Site 2102)', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '5000', 'city': 'Odense', 'state': 'Region Syddanmark', 'country': 'Denmark', 'facility': 'Odense University Hospital ( Site 2101)', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'zip': '54519', 'city': 'Vandœuvre-lès-Nancy', 'state': 'Ain', 'country': 'France', 'facility': 'Institut De Cancerologie De Lorraine ( Site 1010)', 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}, {'zip': '67200', 'city': 'Strasbourg', 'state': 'Alsace', 'country': 'France', 'facility': 'Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1014)', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '14076', 'city': 'Caen', 'state': 'Calvados', 'country': 'France', 'facility': 'Centre François Baclesse ( Site 1009)', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'zip': '21000', 'city': 'Dijon', 'state': 'Cote-d Or', 'country': 'France', 'facility': 'Centre Georges Francois Leclerc ( Site 1008)', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '29200', 'city': 'Brest', 'state': 'Finistere', 'country': 'France', 'facility': 'C.H. regional Unv. de Brest - Hopital La Cavale Blanche - Institut de Cancerologie et d Imagerie ( S', 'geoPoint': {'lat': 48.39029, 'lon': -4.48628}}, {'zip': '25000', 'city': 'Besançon', 'state': 'Franche-Comte', 'country': 'France', 'facility': 'CHU Besançon ( Site 1015)', 'geoPoint': {'lat': 47.24878, 'lon': 6.01815}}, {'zip': '33604', 'city': 'Pessac', 'state': 'Gironde', 'country': 'France', 'facility': 'CHU Bordeaux Haut-Leveque ( Site 1012)', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'zip': '34298', 'city': 'Montpellier', 'state': 'Herault', 'country': 'France', 'facility': 'Institut du Cancer de Montpellier ( Site 1002)', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '37044', 'city': 'Tours', 'state': 'Indre-et-Loire', 'country': 'France', 'facility': 'CHRU de Tours - Hopital Bretonneau ( Site 1018)', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '44805', 'city': 'Saint-Herblain', 'state': 'Loire-Atlantique', 'country': 'France', 'facility': 'Institut De Cancerologie De L Ouest ( Site 1003)', 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'zip': '59000', 'city': 'Lille', 'state': 'Nord', 'country': 'France', 'facility': 'Hôpital Claude Huriez ( Site 1030)', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '94010', 'city': 'Créteil', 'state': 'Val-de-Marne', 'country': 'France', 'facility': 'Hopital Henri Mondor ( Site 1007)', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Saint Louis ( Site 1029)', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '09001', 'city': 'Guatemala', 'state': 'Departamento de Quetzaltenango', 'country': 'Guatemala', 'facility': 'Centro Regional de Sub Especialidades Medicas SA ( Site 0604)'}, {'zip': '01009', 'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'MEDI-K ( Site 0601)', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'zip': '01010', 'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'Oncomedica ( Site 0602)', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'zip': '01010', 'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'Soluciones Gastrointestinales S.A. ( Site 0607)', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Queen Mary Hospital ( Site 4001)', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'city': 'Kowloon', 'country': 'Hong Kong', 'facility': 'Queen Elizabeth Hospital. ( Site 4004)', 'geoPoint': {'lat': 22.31667, 'lon': 114.18333}}, {'zip': '7624', 'city': 'Pécs', 'state': 'Baranya', 'country': 'Hungary', 'facility': 'Pecsi Tudomanyegyetem AOK ( Site 1204)', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '9024', 'city': 'Győr', 'state': 'Győr-Moson-Sopron', 'country': 'Hungary', 'facility': 'Petz Aladar Egyetemi Oktato Korhaz ( Site 1210)', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'zip': '5000', 'city': 'Szolnok', 'state': 'Jász-Nagykun-Szolnok', 'country': 'Hungary', 'facility': 'Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 1203)', 'geoPoint': {'lat': 47.18066, 'lon': 20.19835}}, {'zip': '1122', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Orszagos Onkologiai Intezet ( Site 1207)', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '47014', 'city': 'Meldola', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1313)', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'zip': '33100', 'city': 'Udine', 'state': 'Friuli Venezia Giulia', 'country': 'Italy', 'facility': 'A.O.U. Santa Maria della Misericordia di Udine ( Site 1302)', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Humanitas Research Hospital ( Site 1309)', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '56126', 'city': 'Pisa', 'state': 'Tuscany', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Universitaria Pisana ( Site 1312)', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'zip': '35128', 'city': 'Padua', 'state': 'Veneto', 'country': 'Italy', 'facility': 'Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 1311)', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '88100', 'city': 'Catanzaro', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Mater Domini-Translational Oncology Unit ( Site 1314)', 'geoPoint': {'lat': 38.88247, 'lon': 16.60086}}, {'zip': '50134', 'city': 'Florence', 'country': 'Italy', 'facility': 'Azienda Ospedaliero Universitaria Careggi ( Site 1301)', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'zip': '20132', 'city': 'Milan', 'country': 'Italy', 'facility': 'IRCCS Ospedale San Raffaele di Milano ( Site 1304)', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '20133', 'city': 'Milan', 'country': 'Italy', 'facility': 'Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1306)', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '41124', 'city': 'Modena', 'country': 'Italy', 'facility': 'A.O. Universitaria di Modena ( Site 1307)', 'geoPoint': {'lat': 44.64783, 'lon': 10.92539}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 1305)', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '00168', 'city': 'Roma', 'country': 'Italy', 'facility': 'Universita Cattolica del Sacro Cuore - Policlinico Gemelli ( Site 1310)', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '464-8681', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Aichi Cancer Center Hospital ( Site 9006)', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '260-8717', 'city': 'Chiba', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Chiba Cancer Center ( Site 9023)', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'zip': '277-8577', 'city': 'Kashiwa', 'state': 'Chiba', 'country': 'Japan', 'facility': 'National Cancer Center Hospital East ( Site 9002)', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'zip': '791-0280', 'city': 'Matsuyama', 'state': 'Ehime', 'country': 'Japan', 'facility': 'National Hospital Organization Shikoku Cancer Center ( Site 9019)', 'geoPoint': {'lat': 33.83916, 'lon': 132.76574}}, {'zip': '673-8558', 'city': 'Akashi', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Hyogo Cancer Center ( Site 9014)', 'geoPoint': {'lat': 34.65524, 'lon': 135.00687}}, {'zip': '309-1793', 'city': 'Kasama', 'state': 'Ibaraki', 'country': 'Japan', 'facility': 'Ibaraki Prefectural Central Hospital ( Site 9007)', 'geoPoint': {'lat': 36.38333, 'lon': 140.26667}}, {'zip': '761-0793', 'city': 'Kita-gun', 'state': 'Kagawa-ken', 'country': 'Japan', 'facility': 'Kagawa University Hospital ( Site 9015)'}, {'zip': '241-8515', 'city': 'Yokohama', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Kanagawa Cancer Center ( Site 9004)', 'geoPoint': {'lat': 35.43333, 'lon': 139.65}}, {'zip': '980-8574', 'city': 'Sendai', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Tohoku University Hospital ( Site 9013)', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}, {'zip': '951-8566', 'city': 'Niigata', 'state': 'Niigata', 'country': 'Japan', 'facility': 'Niigata Cancer Center Hospital ( Site 9022)', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}, {'zip': '589-8511', 'city': 'Sayama', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Kindai University Hospital ( Site 9017)', 'geoPoint': {'lat': 34.51685, 'lon': 135.56298}}, {'zip': '565-0871', 'city': 'Suita', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Osaka University Hospital ( Site 9021)', 'geoPoint': {'lat': 34.76143, 'lon': 135.51567}}, {'zip': '569-8686', 'city': 'Takatsuki', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Osaka Medical and Pharmaceutical University Hospital ( Site 9008)', 'geoPoint': {'lat': 34.84833, 'lon': 135.61678}}, {'zip': '362-0806', 'city': 'Kitaadachi-gun', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Saitama Prefectural Cancer Center ( Site 9003)'}, {'zip': '411-8777', 'city': 'Nakatogari', 'state': 'Shizuoka', 'country': 'Japan', 'facility': 'Shizuoka Cancer Center ( Site 9016)', 'geoPoint': {'lat': 35.13526, 'lon': 138.9028}}, {'zip': '113-8677', 'city': 'Bunkyo Ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Tokyo Metropolitan Komagome Hospital ( Site 9028)'}, {'zip': '105-8470', 'city': 'Minato-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Toranomon Hospital ( Site 9026)'}, {'zip': '142-8666', 'city': 'Shinagawa', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Showa University Hospital ( Site 9025)'}, {'zip': '811-1395', 'city': 'Fukuoka', 'country': 'Japan', 'facility': 'National Hospital Organization Kyushu Cancer Center ( Site 9010)', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'zip': '602-8566', 'city': 'Kyoto', 'country': 'Japan', 'facility': 'University Hospital,Kyoto Prefectural University of Medicine ( Site 9027)', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'city': 'Kyoto', 'country': 'Japan', 'facility': 'Kyoto University Hospital ( Site 9011)', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '700-8558', 'city': 'Okayama', 'country': 'Japan', 'facility': 'Okayama University Hospital ( Site 9024)', 'geoPoint': {'lat': 34.65, 'lon': 133.93333}}, {'zip': '541-8567', 'city': 'Osaka', 'country': 'Japan', 'facility': 'Osaka International Cancer Institute ( Site 9009)', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '558-8558', 'city': 'Osaka', 'country': 'Japan', 'facility': 'Osaka General Medical Center ( Site 9018)', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '104-0045', 'city': 'Tokyo', 'country': 'Japan', 'facility': 'National Cancer Center Hospital ( Site 9001)', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '135-8550', 'city': 'Tokyo', 'country': 'Japan', 'facility': 'The Cancer Institute Hospital of JFCR ( Site 9005)', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '160-8582', 'city': 'Tokyo', 'country': 'Japan', 'facility': 'Keio University Hospital ( Site 9020)', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '59100', 'city': 'Lembah Pantai', 'state': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'University Malaya Medical Centre ( Site 9101)'}, {'zip': '93586', 'city': 'Kuching', 'state': 'Sarawak', 'country': 'Malaysia', 'facility': 'Sarawak General Hospital-Radiotherapy Unit ( Site 9100)', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}, {'zip': '50586', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'Hospital Kuala Lumpur ( Site 9104)', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'zip': '013812', 'city': 'Bucharest', 'state': 'București', 'country': 'Romania', 'facility': 'MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2201)', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '400015', 'city': 'Cluj-Napoca', 'state': 'Cluj', 'country': 'Romania', 'facility': 'Cardiomed SRL Cluj-Napoca-Medical Oncology ( Site 2207)', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '407280', 'city': 'Comuna Floresti', 'state': 'Cluj', 'country': 'Romania', 'facility': 'SC Radiotherapy Center Cluj SRL ( Site 2202)'}, {'zip': '905900', 'city': 'Ovidiu', 'state': 'Constanța County', 'country': 'Romania', 'facility': 'Ovidius Clinical Hospital OCH-Oncology and Hematology ( Site 2203)', 'geoPoint': {'lat': 44.258, 'lon': 28.56083}}, {'zip': '200542', 'city': 'Craiova', 'state': 'Dolj', 'country': 'Romania', 'facility': 'S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2204)', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'zip': '300239', 'city': 'Timișoara', 'state': 'Timiș County', 'country': 'Romania', 'facility': 'Policlinica Oncomed SRL ( Site 2206)', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '450054', 'city': 'Ufa', 'state': 'Baskortostan, Respublika', 'country': 'Russia', 'facility': 'Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1507)', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'zip': '194291', 'city': 'Saint-Petersburg', 'state': "Leningradskaya Oblast'", 'country': 'Russia', 'facility': 'GBUZ LOKB ( Site 1502)'}, {'zip': '115478', 'city': 'Moscow', 'state': 'Moscow', 'country': 'Russia', 'facility': 'FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1510)', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '197022', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Academician I.P. Pavlov First St. Petersburg State Medical University ( Site 1519)', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197758', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1503)', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '420029', 'city': "Kazan'", 'state': 'Tatarstan, Respublika', 'country': 'Russia', 'facility': 'Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 150', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'zip': '625041', 'city': 'Tyumen', 'state': 'Tyumen Oblast', 'country': 'Russia', 'facility': 'SAIH of Tyumen reg "Multifield clinical medical center "Medical city" ( Site 1520)', 'geoPoint': {'lat': 57.15222, 'lon': 65.52722}}, {'zip': '168583', 'city': 'Singapore', 'state': 'Central Singapore', 'country': 'Singapore', 'facility': 'National Cancer Centre Singapore ( Site 9201)', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '2193', 'city': 'Johannesburg', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Wits Clinical Research ( Site 9502)', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '4091', 'city': 'Durban', 'state': 'KwaZulu-Natal', 'country': 'South Africa', 'facility': 'The Oncology Centre ( Site 9505)', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '13605', 'city': 'Seongnam-si', 'state': 'Kyonggi-do', 'country': 'South Korea', 'facility': 'Seoul National University Bundang Hospital ( Site 5006)', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'zip': '05505', 'city': 'Songpagu', 'state': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center ( Site 5002)'}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital ( Site 5003)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Samsung Medical Center ( Site 5005)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08308', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Korea University Guro Hospital ( Site 5001)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '39008', 'city': 'Santander', 'state': 'Cantabria', 'country': 'Spain', 'facility': 'Hospital Universitario Marques de Valdecilla ( Site 1602)', 'geoPoint': {'lat': 43.46589, 'lon': -3.80493}}, {'zip': '32005', 'city': 'Ourense', 'state': 'Orense', 'country': 'Spain', 'facility': 'Complexo Hospitalario Universitario de Ourense-MEDICAL ONCOLOGY ( Site 1609)', 'geoPoint': {'lat': 42.33669, 'lon': -7.86407}}, {'zip': '33011', 'city': 'Oviedo', 'state': 'Principality of Asturias', 'country': 'Spain', 'facility': 'Hospital Universitario General de Asturias ( Site 1601)', 'geoPoint': {'lat': 43.36029, 'lon': -5.84476}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital General Universitari Vall d Hebron ( Site 1607)', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28007', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital General Universitario Gregorio Maranon ( Site 1604)', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Virgen del Rocio ( Site 1606)', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '73657', 'city': 'Tainan', 'state': 'Tainan', 'country': 'Taiwan', 'facility': 'Chi Mei Hospital - Liouying Branch-Clinical Trial Center ( Site 6007)', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '833', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Chang Gung Med Foundation. Kaohsiung Branch ( Site 6005)', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40447', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'China Medical University Hospital ( Site 6003)', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '704', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital ( Site 6004)', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '10002', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'National Taiwan University Hospital ( Site 6001)', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '11217', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Taipei Veterans General Hospital ( Site 6006)', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '10700', 'city': 'Bangkok', 'state': 'Bangkok', 'country': 'Thailand', 'facility': 'Faculty of Medicine Siriraj Hospital ( Site 7002)', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '90110', 'city': 'Hat Yai', 'state': 'Changwat Songkhla', 'country': 'Thailand', 'facility': 'Songklanagarind hospital ( Site 7001)', 'geoPoint': {'lat': 7.00836, 'lon': 100.47668}}, {'zip': '01140', 'city': 'Adana', 'country': 'Turkey (Türkiye)', 'facility': 'Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1714)', 'geoPoint': {'lat': 36.98615, 'lon': 35.32531}}, {'zip': '06230', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1701)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '06520', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Memorial Ankara Hastanesi ( Site 1702)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '06800', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1715)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '25070', 'city': 'Erzurum', 'country': 'Turkey (Türkiye)', 'facility': 'Atatürk Üniversitesi-onkoloji ( Site 1712)', 'geoPoint': {'lat': 39.90861, 'lon': 41.27694}}, {'zip': '34303', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 1716)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34384', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Istanbul Okmeydanı Egitim ve Arastirma Hastanesi ( Site 1711)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34732', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Medeniyet Universitesi Tip Fakultesi ( Site 1703)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '14029', 'city': 'Chernihiv', 'state': 'Chernihiv Oblast', 'country': 'Ukraine', 'facility': 'Chernihiv Medical Center of Modern Oncology ( Site 1811)', 'geoPoint': {'lat': 51.50541, 'lon': 31.28656}}, {'zip': '58013', 'city': 'Chernivtsi', 'state': 'Chernivetska Oblast', 'country': 'Ukraine', 'facility': 'Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 1819)', 'geoPoint': {'lat': 48.29045, 'lon': 25.93241}}, {'zip': '50048', 'city': 'Kryviy Rih', 'state': 'Dnipropetrovsk Oblast', 'country': 'Ukraine', 'facility': 'MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 1804)'}, {'zip': '61000', 'city': 'Kharkiv', 'state': 'Kharkivs’ka Oblast’', 'country': 'Ukraine', 'facility': 'Kharkiv Regional Clinical Oncology Center ( Site 1812)', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '61103', 'city': 'Kharkiv', 'state': 'Kharkivs’ka Oblast’', 'country': 'Ukraine', 'facility': 'Institute of General and Emergency Surgery n.a Zaitsev NAMS of Ukraine ( Site 1813)', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '73000', 'city': 'Antonivka Village', 'state': 'Kherson Oblast', 'country': 'Ukraine', 'facility': 'Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council ('}, {'zip': '03022', 'city': 'Kyiv', 'state': 'Kyivska Oblast', 'country': 'Ukraine', 'facility': 'SNPE National Cancer Institute ( Site 1806)', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '33007', 'city': 'Rivne', 'state': 'Rivne Oblast', 'country': 'Ukraine', 'facility': 'Rivne Regional Clinical Hospital ( Site 1817)', 'geoPoint': {'lat': 50.62036, 'lon': 26.23695}}, {'zip': '21029', 'city': 'Vinnytsia', 'state': 'Vinnytsia Oblast', 'country': 'Ukraine', 'facility': 'Podillya Regional Center of Oncology ( Site 1809)', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': '43018', 'city': 'Lutsk', 'state': 'Volyn Oblast', 'country': 'Ukraine', 'facility': 'Volyn Regional Oncological Dispensary ( Site 1816)', 'geoPoint': {'lat': 50.75784, 'lon': 25.35024}}, {'zip': '03126', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Shalimov Institute of Surgery and Transplantation ( Site 1818)', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': 'CB2 2QQ', 'city': 'Cambridge', 'state': 'Cambridgeshire', 'country': 'United Kingdom', 'facility': 'Cambridge University Hospitals NHSFT ( Site 1908)', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'DD2 1SG', 'city': 'Dundee', 'state': 'Dundee City', 'country': 'United Kingdom', 'facility': 'Ninewells Hospital and Medical School ( Site 1907)', 'geoPoint': {'lat': 56.46913, 'lon': -2.97489}}, {'zip': 'NG5 1PF', 'city': 'Nottingham', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Nottingham University Hospital NHS Trust ( Site 1910)', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'EC1A 7BE', 'city': 'London', 'state': 'London, City of', 'country': 'United Kingdom', 'facility': "St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1915)", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NW1 2BU', 'city': 'London', 'state': 'London, City of', 'country': 'United Kingdom', 'facility': 'University College London Hospitals NHS Foundation Trust ( Site 1901)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW3 6JJ', 'city': 'London', 'state': 'London, City of', 'country': 'United Kingdom', 'facility': 'Royal Marsden NHS Foundation Trust ( Site 1905)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'state': 'London, City of', 'country': 'United Kingdom', 'facility': 'Royal Marsden NHS Trust. ( Site 1906)', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'zip': 'EH4 2XU', 'city': 'Edinburgh', 'state': 'Midlothian', 'country': 'United Kingdom', 'facility': 'Western General Hospital ( Site 1912)', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'The Christie NHS Foundation Trust ( Site 1909)', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Sharp & Dohme LLC'}]}, 'ipdSharingStatementModule': {'url': 'https://externaldatasharing-msd.com/', 'ipdSharing': 'YES', 'description': 'https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Eisai Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}